PTGS2 and hepatocellular carcinoma: Since HCC patients with high COX-2 expression exhibit significantly higher numbers of M2 macrophages in TME, which impairs T cell cytotoxicity [146], the treatment with Celecoxib diminishes the suppressive impact on CD8+ T cells by reducing M2-like TAMs.